IRRAS AB (PUBL)INTERIM REPORT JANUARY–MARCH 2019
Focus on US – first sales in US reported early April and acquisition of complementary products in MayFirst quarter, January - March 2019 · Net revenue totaled SEK 0.0 million (5.9). · Operating loss (EBIT) amounted to SEK -39.1 million (-21.1). · Loss after tax totaled SEK -38.7 million (-17.8). · Earnings per share before and after dilution amounted to SEK -1.61 (-0.75). Important events during the quarter First patients in the US successfully treated with IRRAflow®At the beginning of January, the first patients in the United States were treated with our lead